Vaxcyte, Inc.
PCVXNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $8.73B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $39.87$90.75
- Volume (live)
- -
- Avg. volume (3M)
- 3.12M
Vaxcyte (PCVX) Stock Price & Financial Analysis
Vaxcyte Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $60.27 - $62.77 |
|---|---|
| 52-Week High | $90.75 |
| 52-Week Low | $39.87 |
| Open | $62.35 |
| Volume (last close) | 2.06M |
| Average Volume (3M) | 3.12M |
| 50-Day MA | $61.35 |
|---|---|
| 200-Day MA | $56.42 |
| 1-Year Change | +51.08% |
| Market Cap | 8.73B |
|---|---|
| Shares Outstanding | 144.49M |
| Price to Book (P/B) | 3.17 |
| EV/EBITDA | -8.54 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Vaxcyte at a Glance
As of the Oct 23, 2026 close, Vaxcyte (PCVX) has a market capitalization of $8.73B.
As of its latest reported balance sheet, it holds $183.19M in cash and securities against $115.44M of debt, a net cash position of $67.75M.
Vaxcyte does not currently pay a dividend.
The share price is up 51.1% over the past year. At $60.43 (the Oct 23, 2026 close) it sits within its 52-week range of $39.87 to $90.75, above its 200-day moving average of $56.42.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $117.30, 94.1% above the Oct 23, 2026 close.
Frequently Asked Questions About Vaxcyte
What is the current stock price for PCVX?
As of the Oct 23, 2026 close, PCVX stock trades at $60.43. The 52-week range is $39.87–$90.75, with a day range of $60.27–$62.77.
What is the P/E ratio for PCVX?
The P/E ratio (Price-to-Earnings) for PCVX is shown in the Key Statistics section. This valuation metric helps compare Vaxcyte, Inc. to industry peers.
Does PCVX pay dividends?
Vaxcyte does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for PCVX?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for PCVX is Buy. The average 12-month price target is $117.30, a 94.1% upside from the Oct 23, 2026 close of $60.43.
What is the market cap of PCVX?
As of the Oct 23, 2026 close, Vaxcyte's market capitalization is $8.73B, classifying it as a mid-cap company. Vaxcyte operates in the Healthcare sector within the Biotechnology industry.